Skip to the content
Please enable JavaScript in your browser to complete this form.
Attendee details
First Name
*
Last Name
*
Email
*
Member ID (MCHK/HKAM)
Member of
*
[Please select]
Hong Kong College of Community Medicine
The Hong Kong College of Family Physicians
The Hong Kong College of Pathologists
Hong Kong College of Physicians
Hong Kong College of Radiologists
The College of Surgeons of Hong Kong
Medical Council of Hong Kong
Not applicable
Meeting evaluation
Please rate the following aspects of the meeting
Meeting organisation
Excellent
Very good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very good
Item #1 Very good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Platform functionality
*
Excellent
Very good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very good
Item #1 Very good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Meeting time and duration
Excellent
Very good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very good
Item #1 Very good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
*For online attendees only
Please rate the content of the meeting
Agenda and flow
Excellent
Very good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very good
Item #1 Very good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Immune checkpoint inhibitors in cancer presentation by Dr Roland Leung
Excellent
Very good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very good
Item #1 Very good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Case study presentations by:
Dr Foon Yiu Cheung
Excellent
Very good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very good
Item #1 Very good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Dr Darren Poon
Excellent
Very good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very good
Item #1 Very good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Dr Roland Leung
Excellent
Very good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very good
Item #1 Very good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Expert panel discussion
Excellent
Very good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very good
Item #1 Very good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Relevance to clinical practice
Excellent
Very good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very good
Item #1 Very good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Which topic(s) would you like to see covered in future meetings?
Any other comments?
Post-meeting assessment
How likely will you be to consider dual IO therapy (nivolumab + ipilimumab) as a treatment option for your patients with cancer (of the approved indications)?
Very likely
Moderately likely
Neutral
Not likely
How convincing do you find the evidence for the long-term survival benefit of dual IO therapy (nivolumab + ipilimumab)?
Strongly convincing
Somewhat convincing
Neutral
Not convincing
How confident are you in managing adverse events associated with dual IO therapy (nivolumab + ipilimumab)?
Very confident
Moderately confident
Neutral
Not confident
Submit